NVTS is pitched as the cleaner 12-month upside trade: a ~$3 billion company whose pivot from mobile into AI data centers, grid/energy, performance computing, and industrial electrification could be amplified by ClariS and the shift to 800V DC power. The core claim is that if hyperscaler wins, revenue acceleration, 800V adoption, and ClariS validation line up, the stock can still run 500%+ even without billions in near-term revenue. The second half switches to VNRX: a tiny epigenetics name with sepsis, cancer, and pet-cancer tests, multiple near-term catalysts, and a partnership-led model that could unlock outsized leverage if the science and commercialization hold. The overall tone is high-risk, high-upside, with both names framed as volatile and failure-prone.
NVTS is framed for 500%+ upside over the next 12 months, from roughly a $3 billion market cap to as much as $18 billion if the thesis works.
About a year ago NVTS ran from just over $6 to over $31 after the earlier pivot callout, then fell on the tech selloff, the 2026 small-cap drawdown, and still trades more than 2x above those lows.
NVTS's '2.0' repositioning moved from G chips in fast chargers into high-power infrastructure, with focus now on AI data centers, grid and energy infrastructure, performance computing, and industrial electrification.
NVTS says AI infrastructure should be more than one-third of quarterly sales by end-2026, with hyperscaler and data-center programs extending through H2 2026 and into 2027 and backlog at record levels.
This morning NVTS announced the ClariS acquisition for up to about $232.8 million, adding vertical power delivery and integrated voltage regulators aimed at the 'power wall' for AI chips drawing thousands of amps.
ClariS is meant to move power delivery from inches away to millimeters away from the processor, cutting resistance, heat, and wasted electricity while increasing deliverable power.
NVTS already had grid-to-rack pieces: high-voltage silicon carbide, GaN conversion, 800V architectures, solid-state transformers, and higher-voltage SiC; ClariS fills the last few millimeters into the chip.
After ClariS, NVTS says its identified serviceable market opportunity could exceed $8 billion by 2030, more than doubling its prior potential market.
The AI power thesis rests on 800V DC architecture, with more GPUs requiring more electricity and heat management than legacy data-center power systems can handle.
NVTS management expects major AI-power adoption stages over the next year, with 800V power-side cars ramping around mid-2027 and native 800V power into compute trays starting in H2 2027 and accelerating into 2028.
NVTS says it has deepened work with the Nvidia MGX ecosystem and already demonstrated an 800V-to-6V power-delivery board for next-generation 800V AI data-center architecture.
Five catalysts are laid out for the next 12 months: at least one hyperscaler win, sharply faster revenue growth, 800V adoption becoming inevitable, ClariS proving valuable, and the AI semiconductor tape staying bullish.
The bull case does not require billions in revenue over the next 12 months; the stock is expected to rerate on future expectations if 4 of 5 checkpoints hit, possibly all 5.
The bear case is explicit: current revenue is tiny, shareholders have been diluted, NVTS competes with giant semiconductor names, 800V rollout could slip, customers could choose rivals, and the whole growth strategy could fail.
VNRX is pitched as a small-cap epigenetics company with nucleosome-based blood tests for sepsis, early cancer detection, and pet cancer, plus a Japanese diagnostics giant already putting one of its tests onto its own machines.
VNRX runs four pillars: NU.Q Sepsis for sepsis and immune disease, NU.Q Cancer and Capture for human cancer, Seq for multi-cancer early detection, NU.Q Vet for dogs and cats, and NU.Q Discover as a research-tools business selling assay kits to pharma and academic labs.
Recent estimates put global sepsis cases at about 166 million a year, with 2021 sepsis deaths at 31.5% of total global deaths; VNRX pegs NU.Q Sepsis at roughly a $3.8 billion annualized addressable market.
In blinded validation, Capture Seq detected over 95% of stage 1 and stage 2 cancers at 95% specificity; VNRX sizes multi-cancer early detection at about $23 billion annualized, plus another $13 billion if minimal residual disease monitoring works.
The companion-animal pillar is already commercial in more than 20 countries for dogs, while the feline manuscript submitted in May hit 97% specificity, the prototype detected 86% of feline lymphoma, and a working feline test could roughly double that market; VNRX sizes the companion-animal opportunity at over $1 billion annualized.
VNRX's strategy is not to build a global salesforce but to out-license to large diagnostics and liquid-biopsy companies, keeping low incremental cost and high operating leverage through upfronts, milestones, and royalties.
Near-term VNRX catalysts over the next two quarters include the Detects program in France, the feline lymphoma manuscript, a $5 million milestone tied to publication, and the May technical milestone of detecting nucleosomes in capillary blood from critically ill sepsis patients using a lateral-flow prototype.